Prism Medico and Pharmacy Limited (BOM:512217)

Prism Medico and Pharmacy Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Apr 1, 2023	Apr 1, 2022	Apr 1, 2021
Operating Revenue	23.72	6.32	29.25	12.71	84.44	167.64
Other Revenue	-	-	0	-	0	-
Revenue	23.72	6.32	29.25	12.71	84.44	167.64
Revenue Growth (YoY)	-26.85%	-78.40%	130.21%	-84.95%	-49.63%	-37.66%
Cost of Revenue	14.75	4.49	25.61	11.41	86.28	166.68
Gross Profit	8.98	1.83	3.65	1.3	-1.84	0.96
Selling, General & Admin	2.61	2.6	5.02	2.27	3.06	2.58
Other Operating Expenses	0.58	-0.08	-0.61	-0.02	-	-
Operating Expenses	3.23	2.56	4.46	2.32	3.15	2.7
Operating Income	5.75	-0.73	-0.82	-1.02	-4.99	-1.75
Interest Expense	-0.02	-	-	-0	-0.01	-
Interest & Investment Income	-	-	0	-	-	-
Currency Exchange Gain (Loss)	0.09	0.09	0.6	-	-	-
Other Non Operating Income (Expenses)	-0.02	-0.02	-0.07	-0	0	-0
EBT Excluding Unusual Items	5.8	-0.66	-0.29	-1.02	-4.99	-1.75
Pretax Income	5.8	-0.66	-0.28	-1.02	-4.99	-1.75
Income Tax Expense	-0.25	-0.17	-0.07	-0.26	-1.29	-0.45
Net Income	6.04	-0.49	-0.21	-0.76	-3.7	-1.3
Net Income to Common	6.04	-0.49	-0.21	-0.76	-3.7	-1.3
Shares Outstanding (Basic)	606	6	6	6	6	6
Shares Outstanding (Diluted)	606	6	6	6	6	6
Shares Change (YoY)	-	-	3.31%	-3.21%	0.01%	-
EPS (Basic)	0.01	-0.08	-0.04	-0.13	-0.61	-0.21
EPS (Diluted)	0.01	-0.08	-0.04	-0.13	-0.61	-0.21
Gross Margin	37.84%	29.02%	12.46%	10.23%	-2.18%	0.57%
Operating Margin	24.23%	-11.54%	-2.80%	-8.01%	-5.90%	-1.04%
Profit Margin	25.48%	-7.71%	-0.73%	-6.00%	-4.38%	-0.78%
EBITDA	5.79	-0.69	-0.77	-0.95	-4.9	-1.63
EBITDA Margin	24.38%	-10.87%	-2.61%	-7.49%	-5.80%	-0.97%
D&A For EBITDA	0.04	0.04	0.05	0.07	0.09	0.12
EBIT	5.75	-0.73	-0.82	-1.02	-4.99	-1.75
EBIT Margin	24.23%	-11.54%	-2.80%	-8.01%	-5.90%	-1.04%
Revenue as Reported	24.04	6.48	30.48	12.72	84.44	167.64
Advertising Expenses	-	0.17	0.34	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.